EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 128 filers reported holding EXELIXIS INC in Q4 2014. The put-call ratio across all filers is 0.56 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $25,058,296 | -20.9% | 1,115,189 | -16.4% | 0.01% | -28.6% |
Q1 2024 | $31,667,567 | -25.4% | 1,334,495 | -24.5% | 0.01% | -30.0% |
Q4 2023 | $42,428,523 | +34.8% | 1,768,592 | +22.8% | 0.01% | +25.0% |
Q3 2023 | $31,476,717 | +36.0% | 1,440,582 | +18.9% | 0.01% | +33.3% |
Q2 2023 | $23,148,708 | -12.5% | 1,211,340 | -11.1% | 0.01% | -14.3% |
Q1 2023 | $26,462,314 | -27.3% | 1,363,334 | -39.9% | 0.01% | -36.4% |
Q4 2022 | $36,394,054 | +33.1% | 2,268,956 | +30.1% | 0.01% | +22.2% |
Q3 2022 | $27,342,000 | +11.4% | 1,743,710 | +47.9% | 0.01% | +28.6% |
Q2 2022 | $24,549,000 | +18.3% | 1,179,087 | +28.8% | 0.01% | +40.0% |
Q1 2022 | $20,753,000 | +9.8% | 915,445 | -11.5% | 0.01% | 0.0% |
Q4 2021 | $18,902,000 | -26.5% | 1,034,001 | -15.0% | 0.01% | -28.6% |
Q3 2021 | $25,713,000 | +28.3% | 1,216,301 | +10.6% | 0.01% | +40.0% |
Q2 2021 | $20,039,000 | +18.3% | 1,099,821 | +46.7% | 0.01% | 0.0% |
Q1 2021 | $16,941,000 | -13.3% | 749,896 | -23.0% | 0.01% | -16.7% |
Q4 2020 | $19,541,000 | -4.8% | 973,664 | +15.9% | 0.01% | -14.3% |
Q3 2020 | $20,537,000 | +52.0% | 839,905 | +47.6% | 0.01% | +40.0% |
Q2 2020 | $13,509,000 | -16.2% | 569,008 | -39.2% | 0.01% | -28.6% |
Q1 2020 | $16,120,000 | +53.2% | 936,146 | +56.7% | 0.01% | +133.3% |
Q4 2019 | $10,525,000 | -9.2% | 597,361 | -8.9% | 0.00% | 0.0% |
Q3 2019 | $11,594,000 | +30.1% | 655,620 | +57.2% | 0.00% | +50.0% |
Q2 2019 | $8,911,000 | -62.3% | 416,986 | -58.0% | 0.00% | -75.0% |
Q1 2019 | $23,649,000 | +66.2% | 993,669 | +37.4% | 0.01% | +60.0% |
Q4 2018 | $14,229,000 | -39.1% | 723,336 | -45.2% | 0.01% | -28.6% |
Q3 2018 | $23,374,000 | -60.9% | 1,319,072 | -52.5% | 0.01% | -65.0% |
Q2 2018 | $59,727,000 | -35.6% | 2,775,387 | -33.7% | 0.02% | -42.9% |
Q1 2018 | $92,767,000 | -39.9% | 4,188,149 | -17.6% | 0.04% | -37.5% |
Q4 2017 | $154,429,000 | +17.9% | 5,079,903 | -6.1% | 0.06% | +16.7% |
Q3 2017 | $131,020,000 | +1.1% | 5,407,358 | +2.8% | 0.05% | +20.0% |
Q2 2017 | $129,561,000 | +30.6% | 5,260,307 | +14.9% | 0.04% | +21.2% |
Q1 2017 | $99,173,000 | -7.9% | 4,576,550 | -36.6% | 0.03% | -8.3% |
Q4 2016 | $107,669,000 | +11.8% | 7,221,280 | -4.1% | 0.04% | +9.1% |
Q3 2016 | $96,297,000 | +90.1% | 7,529,027 | +16.1% | 0.03% | +73.7% |
Q2 2016 | $50,654,000 | +77.2% | 6,485,818 | -9.2% | 0.02% | +58.3% |
Q1 2016 | $28,582,000 | -42.7% | 7,145,421 | -19.2% | 0.01% | -40.0% |
Q4 2015 | $49,849,000 | +35.9% | 8,838,523 | +35.2% | 0.02% | +25.0% |
Q3 2015 | $36,675,000 | +733400.0% | 6,537,520 | +477788.9% | 0.02% | – |
Q2 2015 | $5,000 | -44.4% | 1,368 | -61.8% | 0.00% | – |
Q1 2015 | $9,000 | -85.5% | 3,583 | -91.6% | 0.00% | – |
Q4 2014 | $62,000 | 0.0% | 42,850 | +4.9% | 0.00% | – |
Q3 2014 | $62,000 | -52.7% | 40,846 | +5.4% | 0.00% | – |
Q2 2014 | $131,000 | -4.4% | 38,735 | +0.0% | 0.00% | – |
Q1 2014 | $137,000 | +813.3% | 38,733 | +1500.5% | 0.00% | – |
Q4 2013 | $15,000 | +7.1% | 2,420 | +2.1% | 0.00% | – |
Q3 2013 | $14,000 | +27.3% | 2,370 | 0.0% | 0.00% | – |
Q2 2013 | $11,000 | – | 2,370 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |